Novartis, Amgen and Banner Alzheimer’s Institute Terminate Two P-II/III Studies of CNP520 (umibecestat) for the Prevention of Alzheimer’s Disease

Novartis, Amgen and Banner Alzheimer's Institute Terminate Two P-II/III Studies of CNP520 (umibecestat) for the Prevention of Alzheimer's Disease

Shots:

  • Novartis, Amgen and Banner Alzheimer’s Institute discontinue two P-II/III studies evaluating the safety & efficacy of CNP520 for the prevention or the delay of the onset of Alzheimer’s disease due to lack of efficacy and worsening of cognitive function in the patients
  • In Aug’2015, Amgen & Novartis collaborated to develop & commercialize therapies for migraine & Alzheimer’s disease, sponsored by both the companies in collaboration with Banner Alzheimer’s Institute
  • CNP520 (PO) is a BACE (aspartyl protease) inhibitor designed to reduce Aβ production to prevent or treat Alzheimer’s disease

Click here to read full press release/ article | Ref: Novartis | Image: Novartis